Report Overview

The Indian Uterine Fibroid Treatment Device Market size was valued at USD XX billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of XX% from 2019 to 2028.

Uterine fibroid (UF) is the benign tumor of the smooth muscle cells formed in the womans uterus and these can lead to excessive menstrual bleeding, pelvic pain, infertility, and frequent urination. Despite being the fact that their cause is still unknown, its risk factors include race, age, familial predisposition, premenopausal state, hypertension, overweight, and diet. It occurs mainly in about 20%40% in women during their reproductive ages. In India, development of efficient and advanced technology, rise in the awareness among people regarding diseases, increasing government initiatives across the nation, growing prevalence of uterine fibroids and change in lifestyle mainly dietary pattern, and rising number of women of reproductive age (WRA) across the nation are the prime growth drivers of the uterine fibroid treatment market.



Market Drivers

High prevalence of uterine fibroids among women across the nation, rising patients preference for minimally invasive procedures, and adoption of technologically advanced products are the major factors expected to drive the market. The growing demand for such procedures due to minimal pain, efficacy, less chance of infection, and speedy recovery as compared to open surgeries is anticipated to boost the demand for uterine fibroids treatment devices.